A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

被引：0
作者：
Elena Elez
Carles Pericay
Manuel Valladares-Ayerbes
Inmaculada Bando
Maria Jose Safont
Javier Gallego
Cristina Grávalos
Antonio Arrivi
Alfredo Carrato
Verónica Conde
Maria José Ortiz
Carlos López
Beatriz Alonso
Inmaculada Ruiz de Mena
Eduardo Díaz-Rubio
Josep Tabernero
Enrique Aranda
机构：
[1] Hospital Universitari Vall d’Hebron,Department of Medical Oncology, Vall d’Hebron Institute of Oncology
[2] Universitat Autònoma de Barcelona,Department of Medical Oncology
[3] C.S. Parc Tauli,Department of Medical Oncology
[4] Complejo Hospitalario Universitario A Coruña,Laboratory Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC)
[5] University Complutense,Department of Medical Oncology
[6] CIBERONC,Department of Medical Oncology
[7] General Universitario de Valencia Hospital,Department of Medical Oncology
[8] General Universitario de Elche Hospital,Department of Medical Oncology
[9] Universitario Doce de Octubre Hospital,Department of Medical Oncology, IRYCIS, CIBERONC
[10] Son Llàtzer Hospital,Department of Medical Oncology
[11] Alcalá University,IMIBIC, Reina Sofía Hospital
[12] Hospital Universitario Ramón y Cajal,Department of Medical Oncology
[13] Virgen de las Nieves Hospital,Department of Medical Oncology
[14] University of Córdoba,IMIBIC, Reina Sofía Hospital
[15] CIBERONC,undefined
[16] Instituto de Salud Carlos III,undefined
[17] Marqués de Valdecilla Hospital,undefined
[18] Universitario de Canarias Hospital,undefined
[19] Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),undefined
[20] University of Córdoba,undefined
[21] CIBERONC,undefined
[22] Instituto de Salud Carlos III,undefined
[23] Clínica Rotger,undefined
来源：
British Journal of Cancer | 2019年 / 121卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：378 / 383
页数：5
相关论文
共 159 条
[1]  
Van Cutsem E(2016)ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann. Oncol. 27 1386-1422
[2]  
Cervantes A(2008)EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J. Clin. Oncol. 26 2311-2319
[3]  
Adam R(2010)Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J. Clin. Oncol. 28 4706-4713
[4]  
Sobrero A(2013)Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Lancet Oncol. 14 749-759
[5]  
Van Krieken JH(2008)K-ras mutations and benefit from cetuximab in advanced colorectal cancer N. Engl. J. Med. 359 1757-1765
[6]  
Aderka D(2013)Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N. Engl. J. Med. 369 1023-1034
[7]  
Sobrero AF(2017)Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials† Ann. Oncol. 28 1713-1729
[8]  
Maurel J(2016)Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study BMC Cancer 16 170-178.e3
[9]  
Fehrenbacher L(2018)Effect of primary tumor location on second- or later-line treatment outcomes in patients with RAS wild-type metastatic colorectal cancer and all treatment lines in patients with RAS mutations in four randomized panitumumab studies Clin. Colorectal Cancer 17 337-345
[10]  
Scheithauer W(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N. Engl. J. Med. 351 205-216
12345678910